Safety of long-term ozanimod treatment for up to 4 years in patients with moderately to severely active Ulcerative Colitis: an interim analysis of the True North open-label extension

被引：0

作者：

Siegel, C. ^{[1
]}

Danese, S. ^{[2
,3
]}

Rubin, D. T. ^{[4
]}

Sabino, J. ^{[5
]}

Long, M. D. ^{[6
]}

Cross, R. K. ^{[7
]}

Armuzzi, A. ^{[8
,9
]}

Blumenstein, I. ^{[10
]}

Kobayashi, T. ^{[11
]}

Lama, S. ^{[12
]}

Charles, L. ^{[12
]}

Cetin, V. ^{[12
]}

Petersen, A. ^{[12
]}

Wu, H. ^{[12
]}

Wang, D. ^{[13
]}

Jain, A. ^{[12
]}

D'Haens, G. ^{[14
]}

机构：

[1] Dartmouth Hitchcock Clin, Gastroenterol, Lebanon, NH USA

[2] IRCCS Osped San Raffaele, Gastroenterol & Endoscopy, Milan, Italy

[3] Univ Vita Salute San Raffaele, Gastroenterol & Endoscopy, Milan, Italy

[4] Univ Chicago Med, Inflammatory Bowel Dis Ctr, Inflammatory Bowel Dis, Chicago, IL USA

[5] Univ Hosp Leuven, Gastroenterol, Dept Gastroenterol, Leuven, Belgium

[6] Univ N Carolina, Chapel Hill, NC USA

[7] Univ Maryland, Sch Med, Gastroenterol & Hepatol, Baltimore, MD 21201 USA

[8] IRCCS Humanitas Res Hosp Rozzano, Inflammatory Bowel Dis, IBD Ctr, Milan, Italy

[9] Humanitas Univ Pieve Emanuele, Dept Biomed Sci, Milan, Italy

[10] Goethe Univ Hosp, Inflammatory Bowel Dis, Frankfurt, Germany

[11] Kitasato Univ, Gastroenterol, Kitasato Inst Hosp, Tokyo, Japan

[12] Bristol Myers Squibb KK, Princeton, NJ USA

[13] Bristol Myers Squibb KK, Tokyo, Japan

[14] Amsterdam Univ Med Ctr, Gastroenterol & Hepatol, Amsterdam, Netherlands

来源：

JOURNAL OF CROHNS & COLITIS | 2024年 / 18卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

DOP16

引用

页码：I100 / I101

页数：2

共 50 条

[31] Extended induction in the True North open-label extension study: clinical outcomes of ∼2 years of ozanimod treatment
Vermeire, S.
Colombel, J. F.
Chiorean, M. V.
Ghosh, S.
Jain, A.
Lawlor, G.
Osterman, M. T.
Wu, H.
Canavan, J. B.
Rubin, D. T.
JOURNAL OF CROHNS & COLITIS, 2023, 17 : 903 - 904
[32] EXTENDED INDUCTION IN THE TRUE NORTH OPEN-LABEL EXTENSION STUDY: CLINICAL OUTCOMES OF ∼2 YEARS OF OZANIMOD TREATMENT
Rubin, David T.
Colombel, Jean Frederic
Chiorean, Michael V.
Ghosh, Subrata
Jain, Anjali
Lawlor, Garrett
Osterman, Mark T.
Wu, Hsiuanlin
Canavan, James B.
Vermeire, Severine
GASTROENTEROLOGY, 2023, 164 (06) : S1102 - S1102
[33] TOFACITINIB, AN ORAL, SMALL MOLECULE JANUS KINASE INHIBITOR, IN THE TREATMENT OF ULCERATIVE COLITIS: ANALYSIS OF AN OPEN-LABEL, LONG-TERM EXTENSION STUDY WITH UP TO 5.9 YEARS OF TREATMENT
Lichtenstein, Gary R.
Loftus, Edward V.
Wei, Shu Chen
Damiao, Aderson O.
Judd, Donna
Lawendy, Nervin
Chan, Gary
Zhang, Haiying
Wang, Wenjin
Thorpe, Andrew J.
Bloom, Stuart
GASTROENTEROLOGY, 2020, 158 (06) : S1190 - S1191
[34] Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial
Cree, Bruce A. C.
Selmaj, Krzysztof W.
Steinman, Lawrence
Comi, Giancarlo
Bar-Or, Amit
Arnold, Douglas L.
Hartung, Hans-Peter
Montalban, Xavier
Havrdova, Eva K.
Sheffield, James K.
Minton, Neil
Cheng, Chun-Yen
Silva, Diego
Kappos, Ludwig
Cohen, Jeffrey A.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (12) : 1944 - 1962
[35] TOFACITINIB, AN ORAL JAK INHIBITOR, IN THE TREATMENT OF ULCERATIVE COLITIS: OPEN-LABEL, LONG-TERM EXTENSION STUDY
Bloom, Stuart
Lichtenstein, Gary R.
Loftus, Edward V.
Lawendy, Nervin
Friedman, Gary S.
Zhang, Haiying
Wang, Wenjin
Thorpe, Andrew J.
Nduaka, Chudy I.
Su, Chinyu
GUT, 2018, 67 : A62 - A63
[36] Tofacitinib for the Treatment of Patients with Juvenile Idiopathic Arthritis: An Interim Analysis of Data up to 5.5 Years from an Open-label, Long-term Extension Study
Brunner, Hermine I.
Akikusa, Jonathan
Al-Abadi, Eslam
Bohnsack, John
Boteanu, Alina Lucica
Chedeville, Gaelle
Cuttica, Ruben
De La Pena, Wendy
Jung, Lawrence
Kasapcopur, Ozgur
Kobusinska, Katarzyna
Schulert, Grant
Neiva, Claudia
Rivas-Chacon, Rafael
Rodriguez, Juan Cruz Rizo
Vazquez-Del Mercado, Monica
Wagner-Weiner, Linda
Weiss, Jennifer E.
Wouters, Carine
Suehiro, Ricardo M.
Posner, Holly
Wouters, Ann
Kanik, Keith S.
Luo, Zhen
Martini, Alberto
Lovell, Daniel J.
Ruperto, Nicolino
ARTHRITIS & RHEUMATOLOGY, 2020, 72
[37] Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study
Nash, Peter
Coates, Laura C.
Kivitz, Alan
Mease, Philip J.
Gladman, Dafna D.
Covarrubias-Cobos, Jose A.
Fitzgerald, Oliver
Fleishaker, Dona
Wang, Cunshan
Wu, Joseph
Hsu, Ming-Ann
Menon, Sujatha
Fallon, Lara
Romero, Ana Belen
Kanik, Keith S.
RHEUMATOLOGY AND THERAPY, 2020, 7 (03) : 553 - 580
[38] Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study
Peter Nash
Laura C. Coates
Alan J. Kivitz
Philip J. Mease
Dafna D. Gladman
José A. Covarrubias-Cobos
Oliver FitzGerald
Dona Fleishaker
Cunshan Wang
Joseph Wu
Ming-Ann Hsu
Sujatha Menon
Lara Fallon
Ana Belén Romero
Keith S. Kanik
Rheumatology and Therapy, 2020, 7 : 553 - 580
[39] Long-Term Efficacy and Safety of Etrasimod for Ulcerative Colitis: Results From the Open-Label Extension of the OASIS Study
Chiorean, Michael
Vermeire, Severine
Panes, Julian
Peyrin-Biroulet, Laurent
Zhang, Jinkun
Sands, Bruce E.
Lazin, Krisztina
Cabell, Chris H.
Naik, Snehal U.
Klassen, Preston
Sandborn, William J.
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S445 - S446
[40] Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study
Vermeire, Severine
Chiorean, Michael
Panes, Julian
Peyrin-Biroulet, Laurent
Zhang, Jinkun
Sands, Bruce E.
Lazin, Krisztina
Klassen, Preston
Naik, Snehal U.
Cabell, Christopher H.
Sandborn, William J.
JOURNAL OF CROHNS & COLITIS, 2021, 15 (06): : 950 - 959

← 1 2 3 4 5 →